Datapoint: FDA Approves TG Therapeutics’ Ukoniq

The FDA on Feb. 5 granted accelerated approval to TG Therapeutics’ Ukoniq for the treatment of relapsed or refractory marginal zone lymphoma that has not responded to previous treatments. Ukoniq’s trial data suggests it may be safer than its rival PI3K inhibitors, including Gilead Sciences’ Zydelig and Bayer’s Aliqopa, and the FDA will not require a black box warning on the new drug. For the treatment of marginal zone lymphoma, Zydelig currently holds preferred formulary placement for 17% of covered lives, compared to Aliqopa’s 4%.

SOURCE: MMIT Analytics, as of 2/10/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 21

Datapoint: Cigna, HelloFresh Partner on Meal Kit Benefits

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 20

Datapoint: SCAN, CareOregon Nix Merger Plans

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
February 15

Datapoint: AbbVie Completes ImmunoGen Deal

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today